Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A.

Cancer Res. 2012 Aug 15;72(16):3928-37. doi: 10.1158/0008-5472.CAN-11-2837. Epub 2012 Jun 12.

PMID:
22693252
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.

Sharma A, Shah SR, Illum H, Dowell J.

Drugs. 2012 Dec 3;72(17):2207-22. doi: 10.2165/11640870-000000000-00000. Review.

PMID:
23116250
[PubMed - indexed for MEDLINE]
3.

Vemurafenib for the treatment of melanoma.

Jordan EJ, Kelly CM.

Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. Review.

PMID:
23094782
[PubMed - indexed for MEDLINE]
4.

Vemurafenib: in unresectable or metastatic melanoma.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000. Review.

PMID:
22946753
[PubMed - indexed for MEDLINE]
5.

[BRAF mutation: a novel approach in targeted melanoma therapy].

Arenbergerová M, Puzanov I.

Klin Onkol. 2012;25(5):323-8. Review. Czech.

PMID:
23102192
[PubMed - indexed for MEDLINE]
6.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
[PubMed - indexed for MEDLINE]
7.

[Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma].

Ladányi A, Balatoni T.

Magy Onkol. 2013 Jun;57(2):100-7. doi: MagyOnkol.2013.57.2.100. Epub 2013 Apr 28. Review. Hungarian. Erratum in: Magy Onkol. 2014 Apr;58(1):51.

PMID:
23795355
[PubMed - indexed for MEDLINE]
Free Article
8.

PLX4032: does it keep its promise for metastatic melanoma treatment?

Livingstone E, Zimmer L, Piel S, Schadendorf D.

Expert Opin Investig Drugs. 2010 Nov;19(11):1439-49. doi: 10.1517/13543784.2010.527945. Epub 2010 Oct 14. Review.

PMID:
20942773
[PubMed - indexed for MEDLINE]
9.

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.

Heakal Y, Kester M, Savage S.

Ann Pharmacother. 2011 Nov;45(11):1399-405. doi: 10.1345/aph.1Q363. Epub 2011 Oct 25. Review.

PMID:
22028422
[PubMed - indexed for MEDLINE]
10.

Vemurafenib: the road to personalized medicine in melanoma.

Amaria RN, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Feb;48(2):109-18. doi: 10.1358/dot.2012.48.2.1745274. Review.

PMID:
22384451
[PubMed - indexed for MEDLINE]
11.

BRAF as a target for cancer therapy.

Dienstmann R, Tabernero J.

Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. Review.

PMID:
21426297
[PubMed - indexed for MEDLINE]
12.

[Melanoma- finally good news].

Wicki A, Arnold AW, Itin PH, Zippelius A.

Praxis (Bern 1994). 2013 May 22;102(11):667-70. doi: 10.1024/1661-8157/a001293. Review. German.

PMID:
23692905
[PubMed - indexed for MEDLINE]
13.

Developing melanoma therapeutics: overview and update.

Korman JB, Fisher DE.

Wiley Interdiscip Rev Syst Biol Med. 2013 May-Jun;5(3):257-71. doi: 10.1002/wsbm.1210. Epub 2013 Feb 13. Review.

PMID:
23408545
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk